Expert Outlook: ResMed Through The Eyes Of 9 Analysts
Expert Outlook: ResMed Through The Eyes Of 9 Analysts
专家展望：9位分析师眼中的瑞思迈
Across the recent three months, 9 analysts have shared their insights on ResMed (NYSE:RMD), expressing a variety of opinions spanning from bullish to bearish.
在最近三个月中，9位分析师分享了他们对瑞思迈（纽约证券交易所代码：RMD）的见解，表达了从看涨到看跌的各种观点。
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
下表简要介绍了他们最近的收视率，展示了过去30天中不断变化的情绪，并将其与前几个月进行了比较。
Analysts have recently evaluated ResMed and provided 12-month price targets. The average target is $203.22, accompanied by a high estimate of $227.00 and a low estimate of $180.00. This current average reflects an increase of 10.52% from the previous average price target of $183.88.
分析师最近对瑞思迈进行了评估，并提供了12个月的价格目标。平均目标为203.22美元，最高估计值为227.00美元，低估值为180.00美元。目前的平均价格比之前的平均目标价183.88美元增长了10.52％。
Investigating Analyst Ratings: An Elaborate Study
调查分析师评级：一项详尽的研究
The standing of ResMed among...
通过对分析...
登录免费看全文
登录/注册